Movatterモバイル変換

Levilimab

From Wikipedia, the free encyclopedia

Anti-IL-6 monoclonal antibody

Pharmaceutical compound

Levilimab is ananti-IL-6 monoclonal antibody initially developed to treatrheumatoid arthritis. In 2020, it was approved as a treatment forCOVID-19 in Russia.^[1]^[2]^[3]

^Harrison, Charlotte (1 August 2020)."Focus shifts to antibody cocktails for COVID-19 cytokine storm".Nature Biotechnology.38 (8):905–908.doi:10.1038/s41587-020-0634-9.ISSN 1546-1696.PMID 32760027.S2CID 220980850.
^Gomon, Y. M.; Strizheletsky, V. V.; Ivanov, I. G.; Balykina, Y. E.; Ermolyev, M. V.; Kolbin, A. S.; Livshits, M. V.; Usmanova, T. A.; Fakhrutdinova, A. M.; Konstantinova, Y. S.; Gubanov, A. P. (2023)."Efficiency of Levilimab in patients with moderate and severe COVID-19".Farmakoekonomika (in Russian). pp. 36–47. Retrieved4 November 2023.
^Lomakin, Nikita V.; Bakirov, Bulat A.; Protsenko, Denis N.; Mazurov, Vadim I.; Musaev, Gaziyavdibir H.; Moiseeva, Olga M.; Pasechnik, Elena S.; Popov, Vladimir V.; Smolyarchuk, Elena A.; Gordeev, Ivan G.; Gilyarov, Mikhail Yu; Fomina, Darya S.; Seleznev, Anton I.; Linkova, Yulia N.; Dokukina, Ekaterina A.; Eremeeva, Anna V.; Pukhtinskaia, Polina S.; Morozova, Maria A.; Zinkina-Orikhan, Arina V.; Lutckii, Anton A. (December 2021)."The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study".Inflammation Research.70 (10–12):1233–1246.doi:10.1007/s00011-021-01507-5.ISSN 1420-908X.PMC 8479713.PMID 34586459.

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Hidden categories: